Investment Thesis
LFTD Partners is a cash-burning pharmaceutical company with severe profitability deterioration: net losses of $24.9M on $36.9M revenue (−67% margin) combined with declining top-line revenue (−1.1% YoY) and catastrophic EPS collapse (−1192% YoY). While low debt and positive operating cash flow provide temporary financial cushion, the company's inability to control operating expenses, combined with zero insider confidence, indicates structural business dysfunction that fundamentals cannot justify.
Strengths
- Strong gross margin of 34.2% indicates underlying product demand
- Positive operating and free cash flow despite net losses
- Low debt burden (0.00x debt-to-equity ratio) provides financial flexibility
Risks
- Severe unprofitability: −$24.9M net loss on modest $36.9M revenue base
- Deteriorating fundamentals: declining revenue combined with exploding losses (EPS down 1192% YoY)
- Negative returns: ROE of −196.8% and ROA of −129.0% indicate capital destruction
- Liquidity concerns: quick ratio of 0.92x falls below 1.0, signaling potential working capital stress
- Zero insider activity in past 90 days suggests lack of management confidence
Key Metrics to Watch
- Operating cash flow trend and sustainability as losses mount
- Revenue stabilization and return to growth
- Operating margin expansion and path to profitability
- Insider buying activity as confidence signal
Financial Metrics
Revenue
36.9M
Net Income
-24.9M
EPS (Diluted)
$-1.68
Free Cash Flow
1.2M
Total Assets
19.3M
Cash
1.8M
Profitability Ratios
Gross Margin
34.2%
Operating Margin
2.5%
Net Margin
-67.3%
ROE
-196.8%
ROA
-129.0%
FCF Margin
3.2%
Balance Sheet & Liquidity
Current Ratio
3.04x
Quick Ratio
0.92x
Debt/Equity
0.00x
Debt/Assets
34.5%
Interest Coverage
3.36x
Long-term Debt
30.8K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T14:45:22.533583 |
Data as of: 2025-12-31 |
Powered by Claude AI